
ADVANCE YOUR CELL THERAPY with our cross-platform capabilities



CellCarta

Achieving the Next Level in **Product Characterization**

Genomic profiling of target cells

- Targeted RNA profiling
- NGS TCR sequencing
- qPCR
- Single-cell RNA sequencing

Cellular profiling

- Flow cytometry/CyTOF
- From absolute cell count to functionality by ICS
- Customized construct-specific panels
- MSD[®] and ELISpot/FluoroSpot

Improving Patient Selection Using Complementary Platforms

Characterization of patients' inflammatory state

- Flow cytometry: immune profiling panels, lymphodepletion (TBNK)
- MSD[®]: cytokine profiling

Tracking key genetic biomarkers

- qPCR: key mutations
- NGS TSO500 panel by Illumina: key tumor biomarkers, MSI, TMB
- Targeted RNA profiling

Monitoring tumor targets

- IHC: key biomarkers including MAGE4, NY-ESO-1, CD19, CD22, CD123, BCMA
- Mass spectrometry: soluble and FFPE BCMA

Monitoring previous treatments

ELISA: detection of rituximab

Monitoring Your Product and Its Therapeutic Response with Biomarker Analysis

Tracking transgene or engineered cell

- Targeted RNA profiling
- NGS TCR sequencing
- qPCR preceded or not by cell sorting (FACS)
- Single-cell RNA sequencing

Immune profiling/cellular kinetics

- Flow cytometry: absolute cell counts (proliferation panels TBNK), surface profiling - including immune checkpoints (PD-1, TIM-3, LAG-3), activation/exhaustion markers, ICS assays
- IHC (single-plex and multiplex): tissue biomarkers for T-cell activation/exhaustion, antigen presentation, immune infiltration, TME

Tracking remaining tumor cells or tumor-specific targets

- Mass spectrometry: BCMA
- IHC
- Flow cytometry

Evaluating Combination Therapy

Pharmacokinetics (PK) of other biologics

- MSD®
- ELISA

Simplifying Toxicity Assessment

Measurement of cytokine release syndrome (CRS)

- MSD[®]
- ELISA

NGS: Next Generation Sequencing, TCR: T-cell receptor, ICS: intracellular cytokine staining, MSD®: Meso Scale Discovery®, MSI: microsatellite instability, TMB: tumor mutational burden, IHC: immunohistochemistry

CellCarta

For more information on how CellCarta can partner with you. please contact us:

HEADQUARTERS 201 President Kennedy Ave., Suite 3900 Montreal, Quebec, Canada H2X 3Y7 Phone: +1 514 360 3600

www.cellcarta.com info@cellcarta.com Toll Free: + 1 877 776 3443

_CellTherapy_2021-11-04

Щ